Home › Funds › Hoffman, Alan N Investment Management › VRTX
Hoffman, Alan N Investment Management position in VRTX
VERTEX PHARMACEUTICALS INC · Health Care
Hoffman, Alan N Investment Management reported holding 440 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$230K, representing 0.12% of its reported portfolio and ranking #14 among its reported holdings. Hoffman, Alan N Investment Management has disclosed VRTX holdings in 5 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Hoffman, Alan N Investment Management's VRTX position evolved
Hoffman, Alan N Investment Management first disclosed a stake in VRTX in Q2 2024 at 440 shares (US$206K). The position peaked in Q3 2026 at 440 shares, worth US$230K. Across 5 filings, Hoffman, Alan N Investment Management held the position steady without any share-count change. The most recent filing (Q3 2026) shows 440 shares valued at US$230K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 440 | $206.24K | New |
| Q3 2024 | 440 | $204.63K | Hold |
| Q1 2025 | 440 | $213.32K | New |
| Q2 2026 | 440 | $218.56K | New |
| Q3 2026 | 440 | $230.04K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRTX and 13F data
VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRTX
- Capital World Investors 25.97M sh · $13.58B · Q3 2026
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Capital Research Global Investors 17.81M sh · $9.31B · Q3 2026
- Invesco Ltd 8.28M sh · $4.33B · Q3 2026
- Capital International Investors 5.06M sh · $2.65B · Q3 2026
- Franklin Resources 4.46M sh · $2.45B · Q3 2026
- LOOMIS SAYLES & CO L P 3.62M sh · $1.89B · Q3 2026
- JENNISON ASSOCIATES LLC 3.00M sh · $1.49B · Q2 2026
- ALLIANCEBERNSTEIN L.P. 3.02M sh · $1.35B · Q2 2026
- VICTORY CAPITAL MANAGEMENT INC 2.56M sh · $1.34B · Q3 2026
- Janus Henderson Group 2.13M sh · $951.79M · Q1 2026
More on Hoffman, Alan N Investment Management
FAQ
How long has Hoffman, Alan N Investment Management held VRTX?
Hoffman, Alan N Investment Management has disclosed VRTX holdings in 5 of the last 10 reported quarters, going back to Q2 2024.
What is Hoffman, Alan N Investment Management's current position in VRTX?
As of Q3 2026, Hoffman, Alan N Investment Management holds 440 shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $230.04K, representing 0.12% of its reported portfolio and ranking #14.
Has Hoffman, Alan N Investment Management been buying or selling VRTX?
In the latest 13F filing (Q3 2026), Hoffman, Alan N Investment Management held unchanged its position in VRTX. The position peaked in Q3 2026 at 440 shares.
Which other funds hold VRTX?
Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.